GenMark Reports Fourth Quarter and Full Year 2014 Results
GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fourth quarter and year ended December 31, 2014.
Revenue for the fourth quarter of 2014 was $9.8 million, an increase of 52% over the prior year period. Full year 2014 revenue grew to $30.6 million, an increase of 59% versus 2013 base business revenue, which excludes revenues from former customer NMTC. During the quarter, 38 additional XT-8 analyzers were placed in end-user laboratories, resulting in a total installed base of 540 analyzers within the U.S. market at year end.
Gross profit for the fourth quarter was $6.0 million, or 61% of revenue, compared with $3.0 million, or 47% of revenue in same period of 2013. Full year 2014 gross profit was $17.5 million, or 57% of revenue.
“We are very pleased with our results in 2014, both in terms of revenue growth and gross margin improvement,” said Hany Massarany, President and Chief Executive Officer of GenMark. “In 2015, we will continue to grow and support our XT-8 business in the US market, while remaining very focused on launching ePlex in Europe in the middle of the year,” added Massarany.
Operating expenses for the fourth quarter of 2014 were $14.7 million compared to $13.3 million in the same period for 2013. The increase was mainly driven by Research and Development expenses as the Company completed the development phase of the ePlex system. For the full year, 2014 operating expenses were $56.5 million, an increase of $9.8 million over 2013 primarily driven by Research and Development investment in ePlex.
Loss per share was $0.21 per share for the fourth quarter of 2014 compared to a loss of $0.26 per share in the same period of 2013. For the full year 2014, loss per share was $0.93.
The Company ended the year with $70.5 million in cash and cash equivalents and intends to continue utilizing its cash balances to invest in the global commercialization of the ePlex platform. As previously announced, the Company also established a debt facility for up to $40 million to provide additional capital to launch ePlex internationally as well as domestically.
For full year 2015, the Company expects revenue in the range of $38 to $40 million and Gross Margin in the range of 53-55%. The Company expects to place approximately 50 XT-8 analyzers in the first half of 2015.
The Company will be hosting a conference call to discuss fourth quarter results in further detail and release 2015 guidance on Tuesday, February 24, 2015 starting at 4:30 p.m. Eastern Time. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 61540488 approximately five minutes prior to the start time.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor(R) detection technology, GenMark’s eSensor(R) XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. The eSensor(R) detection technology is also incorporated into GenMark’s sample-to-answer system, ePlexTM. For more information, visit www.genmarkdx.com.
SAFE HARBOR STATEMENT
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our future financial performance, the timely commercialization of our ePlex system, and the availability of future financing, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully commercialize our ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
|GENMARK DIAGNOSTICS, INC.|
|CONSOLIDATED BALANCE SHEETS|
|(In thousands, except par value)|
|As of December 31,|
|Cash and cash equivalents||$||36,855||$||35,723|
|Accounts receivable – net of allowances of $2,702 and $2,736, respectively||4,889||2,859|
|Prepaid expenses and other current assets||575||552|
|Total current assets||78,107||111,102|
|Property and equipment, net||11,052||8,591|
|Intangible assets, net||1,870||1,197|
|Other long-term assets||183||106|
|Other current liabilities||3,653||2,962|
|Total current liabilities||12,293||10,237|
|Other noncurrent liabilities||208||748|
|Preferred stock, $0.0001 par value; 5,000 authorized, none issued||–||–|
|Common stock, $0.0001 par value; 100,000 authorized; 41,859 and 41,520 shares issued and outstanding as of December 31, 2014 and December 31, 2013, respectively||4||4|
|Additional paid-in capital||340,502||333,363|
|Accumulated other comprehensive income (loss)||(10||)||10|
|Total stockholders’ equity||78,024||109,168|
|Total liabilities and stockholders’ equity||$||91,970||$||121,754|
|GENMARK DIAGNOSTICS, INC.|
|CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS|
|(In thousands, except per share data)|
|Three Months Ended||Twelve Month Ended|
|December 31||December 31,|
|License and other revenue||91||(125||)||266||200|
|Cost of revenues||3,827||3,420||13,127||15,570|
|Sales and marketing||3,112||2,988||12,629||12,818|
|General and administrative||3,018||4,041||12,069||11,836|
|Research and development||8,526||6,274||31,823||22,060|
|Total operating expenses||14,656||13,303||56,521||46,714|
|Loss from operations||(8,657||)||(10,271||)||(39,054||)||(34,880||)|
|Other income (expense)|
|Other income (expense)||27||(469||)||(6||)||897|
|Total other income (expense)||63||(347||)||218||1,281|
|Loss before income taxes||(8,594||)||(10,618||)||(38,836||)||(33,599||)|
|Income tax expense (benefit)||18||14||(573||)||44|
|Net loss per share, basic and diluted||$||(0.21||)||$||(0.26||)||$||(0.93||)||$||(0.95||)|
|Weighted average number of shares outstanding, basic and diluted||41,569||40,957||41,346||35,253|
|Other comprehensive loss|
|Net unrealized losses on marketable securities, net of tax||(14||)||(16||)||(20||)||(4||)|
|GENMARK DIAGNOSTICS, INC.|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Year ended December 31,|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Depreciation and amortization||2,656||2,530||1,198|
|Amortization of premiums on marketable securities||702||314||–|
|Provision for bad debt||–||2,721||(24||)|
|Non-cash inventory adjustments||450||1,779||(482||)|
|Gain on sales of investment in preferred stock||–||(1,392||)||–|
|Elimination of cumulative foreign currency translation adjustments upon liquidation of foreign subsidiary||–||450||–|
|Impairment of intangible asset||–||1,624||–|
|Other non-cash adjustments||185||–||–|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other assets||(184||)||(119||)||68|
|Net cash used in operating activities||(29,572||)||(23,796||)||(16,243||)|
|Change in restricted cash||–||585||(1,343||)|
|Purchase of marketable securities||(28,054||)||(76,190||)||(1,000||)|
|Payments for intellectual property licenses||(350||)||(882||)||(1,327||)|
|Purchases of property and equipment||(5,726||)||(4,270||)||(3,476||)|
|Proceeds from sales of marketable securities||7,497||6,643||–|
|Maturities of marketable securities||56,050||1,550||5,000|
|Net cash provided by (used in) investing activities||29,417||(72,564||)||(2,146||)|
|Proceeds from issuance of common stock||812||86,547||48,300|
|Cost incurred in conjunction with public offering||–||(5,510||)||(3,211||)|
|Proceeds from borrowings||–||166||991|
|Principal repayment of borrowings||(56||)||(766||)||(1,984||)|
|Proceeds from stock option exercises||531||396||223|
|Net cash provided by financing activities||1,287||80,833||44,319|
|Net (decrease) increase in cash and cash equivalents||1,132||(15,527||)||25,930|
|Cash and cash equivalents at beginning of period||35,723||51,250||25,320|
|Cash and cash equivalents at end of period||$||36,855||$||35,723||$||51,250|
|Non-cash investing and financing activities:|
|Property and equipment purchased with capital lease||$||–||$||–||$||109|
|Transfer of systems from property and equipment into inventory||$||256||$||575||$||223|
|Property and equipment costs incurred but not paid included in accounts payable||$||124||$||603||$||592|
|Leasehold improvements related to lease incentives||$||–||$||–||$||1,359|
|Intellectual property acquisition included in other noncurrent liabilities||$||550||$||450||$||–|
|Offering costs incurred but not paid included in other liabilities||–||65||–|
|Supplemental cash flow disclosures:|
|Cash paid for interest||$||20||$||19||$||90|
|Cash received for interest||$||244||$||403||$||42|
|Cash paid for income taxes, net||$||24||$||21||$||91|
Sorry. No data so far.